Jun Guo

Peking University - Key Laboratory of Carcinogenesis and Translational Research

No. 38 Xueyuan Road

Haidian District

Beijing, Beijing 100871

China

SCHOLARLY PAPERS

4

DOWNLOADS

197

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (4)

1.

Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b Trial

Number of pages: 148 Posted: 24 Jan 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Harvard University - Harvard Medical School and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 82 (409,600)

Abstract:

Loading...

Mucosal, Melanoma, anti-PD-1 antibody, Axitinib

2.

Efficacy and Safety of RC48-ADC, a Her2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Phase 2, Open-Label, Multi-Centre, Single-Arm Study

Number of pages: 118 Posted: 02 Oct 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Chinese Academy of Medical Sciences - State Key Lab of Molecular Oncology, Sun Yat-sen University (SYSU) - Department of Medical Oncology, Tianjin Medical University, Chongqing University, Shandong University - Qilu Hospital, Sichuan University - Department of Medical Oncology, Peking University - Department of Urology, Government of the People's Republic of China - Weifang No. 2 People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Pathology, Central South University - Affiliated Cancer Hospital, Anhui Provincial Cancer Hospital, Chinese Academy of Medical Sciences - National Cancer Center, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, RemeGen, Ltd., Chinese Academy of Medical Sciences - State Key Lab of Molecular Oncology and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 70 (447,277)

Abstract:

Loading...

3.

Kinetic Inference Resolves Epigenetic Mechanism of Drug Resistance in Melanoma

Number of pages: 75 Posted: 21 Aug 2019
California Institute of Technology - Division of Chemistry and Chemical Engineering, University of California, Los Angeles (UCLA) - Department of Molecular and Medical Pharmacology (DMMP), California Institute of Technology - Division of Biology and Biological Engineering, Institute for Systems Biology, Peking University - Key Laboratory of Carcinogenesis and Translational Research, California Institute of Technology - Division of Chemistry and Chemical Engineering, California Institute of Technology - Division of Chemistry and Chemical Engineering, California Institute of Technology - Division of Biology and Biological Engineering, University of California, Los Angeles (UCLA) - Department of Medicine, City of Hope - Department of Molecular and Cellular Biology, California Institute of Technology - Division of Chemistry and Chemical Engineering, Shanghai Jiao Tong University (SJTU) - MOE Key Laboratory of Systems Biomedicine (KLSB), Shanghai Jiao Tong University (SJTU) - MOE Key Laboratory of Systems Biomedicine (KLSB), University of California, Los Angeles (UCLA) - Department of Molecular and Medical Pharmacology (DMMP), Institute for Systems Biology, Institute for Systems Biology, Institute for Systems Biology, California Institute of Technology - Division of Chemistry and Chemical Engineering, California Institute of Technology - Division of Chemistry and Chemical Engineering, University of California, Los Angeles (UCLA) - Department of Molecular and Medical Pharmacology (DMMP), Fudan University - Shanghai Cancer Center (FUSCC), City of Hope - Department of Molecular and Cellular Biology, City of Hope - Department of Molecular and Cellular Biology, Institute for Systems Biology, Shanghai Jiao Tong University (SJTU) - MOE Key Laboratory of Systems Biomedicine (KLSB), University of California, Los Angeles (UCLA) - Department of Molecular and Medical Pharmacology (DMMP), University of California, Los Angeles (UCLA) - Department of Medicine, California Institute of Technology - Division of Biology and Biological Engineering, Peking University - Key Laboratory of Carcinogenesis and Translational Research, California Institute of Technology - Division of Chemistry and Chemical Engineering and Institute for Systems Biology
Downloads 38 (583,146)
Citation 2

Abstract:

Loading...

non-genetic drug resistance, epigenetic plasticity, chromatin remodeling, melanoma, targeted therapy resistance, multi-omics characterization, systems biology, information theory, dynamic systems, histone modification

4.

Safety and Efficacy of Pucotenlimab (HX008) - A Humanized Immunoglobulin G4 Monoclonal Antibody in Patients with Locally Advanced or Metastatic Melanoma: A Single-Arm, Multicenter, Phase II Study

Number of pages: 9 Posted: 02 Jun 2022
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Fujian Medical University - Fujian Cancer Hospital, Fudan University - Shanghai Cancer Center (FUSCC), Nanjing University - The Affiliated Drum Tower Hospital, Sichuan University - West China Hospital, Zhejiang University - Sir Run Run Shaw Hospital, The First Affiliated Hospital of Zhengzhou University, Jinan University - First Affiliated Hospital, Tongji University - Shanghai Tenth People's Hospital, Xinjiang Medical University - Affiliated Cancer Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Taizhou Hanzhong Biomedical Co., Ltd. (A member of Lepu Biopharma Co., Ltd.), The First Hospital of Jilin University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Taizhou Hanzhong Biomedical Co., Ltd. (A member of Lepu Biopharma Co., Ltd.), Taizhou Hanzhong Biomedical Co., Ltd. (A member of Lepu Biopharma Co., Ltd.), The First Hospital of Jilin University and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 7 (820,319)

Abstract:

Loading...

Pucotenlimab, HX008, Anti-PD-1 antibody, Melanoma, Phase II study